Univo Pharmaceuticals (XTAE:UNVO-M) EBIT per Share : ₪-9,666.00 (TTM As of Jun. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Univo Pharmaceuticals EBIT per Share?

Univo Pharmaceuticals's EBIT per Share for the three months ended in Jun. 2022 was ₪-6,967.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 was ₪-9,666.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Univo Pharmaceuticals's EBIT per Share or its related term are showing as below:

XTAE:UNVO-M's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 9.3
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Univo Pharmaceuticals's EBIT for the three months ended in Jun. 2022 was ₪-20.90 Mil.

Univo Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Univo Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Univo Pharmaceuticals EBIT per Share Chart

Univo Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

Get a 7-Day Free Trial

-488.00

-56,623.00

-5,694.00

2.00

-222.33

Univo Pharmaceuticals Quarterly Data
	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EBIT per Share	Get a 7-Day Free Trial													3,248.00	-500.00	-1,409.33	-789.67	-6,967.00

Univo Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Univo Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.667	/	0.003
=	-222.33

Univo Pharmaceuticals's EBIT per Share for the quarter that ended in Jun. 2022 is calculated as

	EBIT per Share		(Q: Jun. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.901	/	0.003
=	-6,967.00

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-9,666.00

Univo Pharmaceuticals (XTAE:UNVO-M) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Univo Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Univo Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Univo Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Univo Pharmaceuticals Ltd (XTAE:UNVO-M) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Harshar 20, Ashkelon, ISR, 7878329

Website

https://www.univopharma.com

Univo Pharmaceuticals Ltd is engaged in designing & developing drugs for the treatment of brain disorders. The company provides cannabis-based products for distribution and export to the international markets.

Univo Pharmaceuticals Headlines

No Headlines